


JO19 Rec'd PCT/PTO 13 JUN 2001

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 5-93)		ATTORNEY'S DOCKET NUMBER  A3400PCT-US  U.S. APPLICATION NO. (If known, enter 37 C.F.R. 1.53) <b>097868026</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES          DESIGNATED/ELECTED OFFICE (DO/EO/US)          CONCERNING A FILING UNDER 35 U.S.C. 371</b>		
INTERNATIONAL APPLICATION NO.  PCT/IB00/00165	INTERNATIONAL FILING DATE  5 January 2000	PRIORITY DATE CLAIMED  U.S. No. 60/114,758 (05.01.99)
TITLE OF INVENTION  HUMAN ADULT ASTROCYTES, THEIR PREPARATION AND USES THEREOF		
APPLICANT(S) FOR DO/EO/US  Ridet, Jean-Luc; and MALLET, Jacques		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)), and Power of Attorney (unexecuted). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. Below concern other document(s) or information included: 11. <input type="checkbox"/> An information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input type="checkbox"/> Other items or information		
CERTIFICATION UNDER 37 CFR 1.10		
"Express Mail" Mailing Number EL68515422US I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated Above and is addressed to Box PCT, Assistant Commissioner for Patent, Washington, D.C. 20531, Attn: EO/US <u>William C. Coppola</u> (Type or print name of person mailing paper)		Date of Deposit June 14, 2001  (Signature of person mailing paper)

[illegible]

# HUMAN ADULT ASTROCYTES, THEIR PREPARATION AND USES THEREOF

## Field of the Invention

This invention relates to the field of neurobiology. More specifically, it relates  
5 to purified human adult astrocytes, to methods for their preparation, and to their use,  
especially for the treatment of neurodegenerative disorders or trauma to the central  
nervous system.

## Background of the Invention

10

### Astrocytes

The combination of cell transplantation and gene transfer techniques provides a  
therapeutic approach to neurodegenerative diseases and traumatic injury. Several cell  
types, e.g. progenitor cells, neurons, glial cells, fibroblasts and myoblasts, have been  
15 investigated as vehicles for gene delivery to the central nervous system (CNS) (Wolff et  
al., 1989; Horellou et al., 1990a,b; Fisher et al., 1991, 1993, Gage et al., 1995; Sabate et  
al., 1995; Fisher, 1997; Martinez-Serrano and Bjorklund, 1997). Particular attention has  
been paid to the therapeutic activity of genetically engineered astrocytes (Cunningham et  
al., 1991, 1994; La Gamma et al., 1993; Castillo et al., 1994; Pundt et al., 1995;  
20 Lundberg et al., 1996; Lin et al., 1997). Astrocytes are especially targeted for brain  
repair because they are normal CNS constituents, are endowed with efficient secretory  
mechanisms and provide support to neurons through the release of trophic factors that  
promote their survival, differentiation and regeneration. In addition, they can be  
expanded in culture and genetically engineered to express foreign transgenes. Recently,  
25 human fetal astrocytes arising from legal abortions have been cultured and successfully  
transduced with a retrovirus driving the expression of active NGF (Lin et al., 1997).

Human adult astrocytes are more relevant for human brain repair, since they  
allow autologous *ex vivo* gene transfer, thus obviating immunological rejection and side  
effects of immunosuppressors. In recent studies that attempted to culture human adult  
30 astrocytes, contamination with microglial cells was reported (Yong et al., 1991, 1992).

### Gene Therapy

*Ex vivo* gene transfer involves the delivery of therapeutic cells to a patient (Wolff et al., 1989; Horellou et al., 1990a,b; Fisher et al., 1991, 1993, Gage et al., 1995; Sabate et al., 1995; Fisher, 1997; Martinez-Serrano and Bjorklund, 1997; Taylor, 1997). The use of immortalized cell lines for gene therapy is of limited value, since they retain tumorigenic properties. In contrast, primary cultured cells are more suitable. One of the best cell types for *ex vivo* gene transfer and subsequent transplantation is astrocytes (La Gamma et al., 1993; Castillo et al., 1994; Cunningham et al., 1994; Ridoux et al., 1994; Pundt et al., 1995; Lundberg et al., 1996; Lin et al., 1997), which are normally present in the CNS as the major supporting cells with efficient secretory machinery. Grafted astrocytes, previously modified to produce enzymes, neurotransmitters or trophic factors, can integrate and function suitably in the CNS (see refs in Taylor, 1997). Rat primary cultured astrocytes have been genetically engineered to produce NGF and BDNF, and survive after transplantation into the brain (Cunningham et al., 1991, 1994; Yoshimoto et al., 1995).

Recently, the interest in human astrocytes has grown (Yong et al., 1991, 1992; Aloisi et al., 1992; Perzelova and Mares, 1993; Pundt et al., 1995; Lin et al. 1997). Yong and colleagues (1992) reported that up to 80% of primary cultured cells were macrophages/microglial cells. After removal of most of the oligodendrocytes and microglial cells, 70% of the cells were astrocytes (Yong et al., 1992). The presence of microglial cells in astrocyte cultures may cause undesirable effects both *in vitro* and *in vivo*, since they proliferate actively and are major components of the immune cell population. Therefore, there is a need for a method to produce a population of astrocytes that is free of contaminating microglial cells. The present invention addresses this need, as discussed below. The present invention overcomes the disadvantages of impure preparations of astrocytes, and provides a cell preparation suitable for treating trauma to the CNS and for the treatment of neurodegenerative disorders, such as Parkinson's, Huntington's or Alzheimer's disease.

The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.

### Summary of the Invention

The present invention provides purified astrocytes and methods for their  
5 preparation. In a preferred embodiment, the astrocytes are human, adult astrocytes.

Therefore, the invention provides a method of producing an essentially pure  
population of astrocytes comprising: a) introducing a preparation of astrocytes to a  
culture vessel, b) incubating the astrocytes from step a) under conditions enabling  
attachment of the astrocytes to the culture vessel, and c) removing cells which have not  
10 attached to the culture vessel at a time of about 48 hours from the beginning of step a).  
By being "essentially pure" the cell population is at least 75% astrocytes, preferably at  
least 85% astrocytes, more preferably at least about 95% astrocytes, and most preferably  
greater than about 98% astrocytes. The term "about" means within 20%, preferably  
within 10%, and more preferably within 5% of a given value or range. A "culture  
15 vessel" can be any support suitable for cell attachment and growth including, but not  
limited to, a culture dish or flask.

In a preferred embodiment, the astrocytes are human astrocytes. More  
preferably, they are human adult astrocytes.

Astrocytes produced according to the present invention are essentially free of  
20 microglial cells. That is, the presence of microglial cells is not detected by OX42  
immunostaining and labeling with B<sub>4</sub> isolectin from *Griffonia simplicifolia*.

In one aspect of the method of the invention, an exogenous nucleic acid may be  
introduced into the astrocytes. The nucleic acid may be introduced into the astrocytes  
with a viral vector, by calcium-phosphate precipitation, liposome-mediated transfection,  
25 cationic lipid transfection, or lipopolyamine-mediated transfection. Preferably, the  
nucleic acid encodes a neuroactive substance.

The invention also provides an essentially pure population of astrocytes.  
Preferably, the astrocytes are human astrocytes. More preferably, they are human adult  
astrocytes. A population of astrocytes produced according to the present invention is  
30 essentially free of microglial cells.

In one aspect of the invention, the population of astrocytes comprises an  
exogenous nucleic acid. In a preferred embodiment, the nucleic acid encodes a

neuroactive substance. The nucleic acid may be DNA or RNA. In one aspect, the nucleic acid is a DNA encoding a protein, polypeptide or peptide. The protein, polypeptide or peptide may be a growth factor, neurotrophic factor, or enzyme. Alternatively, the nucleic acid may be a DNA encoding an antisense-RNA or a ribozyme. In a preferred embodiment, the nucleic acid is operably linked to a regulatory region comprising a regulatable promoter, an inducible promoter, a neural cell-specific promoter or a viral promoter.

The present invention also provides an implant comprising a population of essentially pure astrocytes. The invention further provides a composition comprising an essentially pure population of astrocytes comprising an exogenous nucleic acid encoding a neuroactive substance.

These and other objects are addressed by this invention, which is explained in greater detail in the attached drawings and the following Detailed Description and Examples.

#### **Brief Description of the Drawings**

**Figure 1:** Primary culture from human adult cerebral cortex.

(A), Phase contrast micrographs showing low magnification (x70) of primary cultures of human adult astrocytes. (B), Higher magnification (x560) of a dividing flat cell at telophasis stage.

**Figure 2:** Immunocytochemical characterization of primary cultures of human adult astrocytes.

Low magnification (x280) micrographs illustrating that all the cells were GFAP- (A) and S100 $\beta$ -positive (B).

**Figure 3:** *In vitro* proliferation of human adult astrocytes.

Proliferation rates are expressed as percent of increase in cell number since  $t_0$ . Human adult astrocytes proliferated *in vitro* when cultured in FCS. Note that the cells proliferated twice as fast when cultured in the presence of 20% FCS than in 10% FCS (A). NGF and bFGF (50 ng/ml) did not have any mitogenic effects on primary cultured

human adult astrocytes (B). Note that when HS was added to the medium, most of the cells did not attach onto the culture dish and they were removed with the medium.

**Figure 4:** TH immunocytochemistry after adenoviral transduction of human adult astrocytes.

(B), Low magnification (x70) micrographs illustrating that 50-60% of the cells were TH-positive one week post-infection (A, non-infected cells). (C), Higher magnification (x560) illustrating transduced astrocytes containing hTH.

**Figure 5:** TH activity in transduced human adult astrocytes


TH activity was detected within the first week post-infection and then increased to 35650 pmol [<sup>3</sup>H] H<sub>2</sub>O/mg prot./h on day 14. Note that TH activity decreased by at least 10 fold in the presence of doxycycline 14 days post-infection.

## **Detailed Description of the Invention**

### **Definitions**

The following defined terms are used throughout the present specification, and should be helpful in understanding the scope and practice of the present invention.

A "polypeptide" is a polymeric compound comprised of covalently linked amino acid residues. Amino acids have the following general structure:



Amino acids are classified into seven groups on the basis of the side chain R: (1) aliphatic side chains, (2) side chains containing a hydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) side chains containing an acidic or amide group, (5) side

chains containing a basic group, (6) side chains containing an aromatic ring, and (7) proline, an imino acid in which the side chain is fused to the amino group.

A "**protein**" is a polypeptide which plays a structural or functional role in a living cell.

5       The polypeptides and proteins of the invention may be glycosylated or unglycosylated.

      A "**variant**" of a polypeptide or protein is any analogue, fragment, derivative, or mutant which is derived from a polypeptide or protein and which retains at least one biological property of the polypeptide or protein. Different variants of the polypeptide  
10 or protein may exist in nature. These variants may be allelic variations characterized by differences in the nucleotide sequences of the structural gene coding for the protein, or may involve differential splicing or post-translational modification. The skilled artisan can produce variants having single or multiple amino acid substitutions, deletions, additions, or replacements. These variants may include, inter alia: (a) variants in which  
15 one or more amino acid residues are substituted with conservative or non-conservative amino acids, (b) variants in which one or more amino acids are added to the polypeptide or protein, (c) variants in which one or more of the amino acids includes a substituent group, and (d) variants in which the polypeptide or protein is fused with another polypeptide such as serum albumin. The techniques for obtaining these variants,  
20 including genetic (suppressions, deletions, mutations, etc.), chemical, and enzymatic techniques, are known to persons having ordinary skill in the art.

      If such allelic variations, analogues, fragments, derivatives, mutants, and modifications, including alternative mRNA splicing forms and alternative post-translational modification forms result in derivatives of the polypeptide which retain any  
25 of the biological properties of the polypeptide, they are intended to be included within the scope of this invention.

      A "**nucleic acid**" is a polymeric compound comprised of covalently linked subunits called nucleotides. Nucleic acid includes polyribonucleic acid (RNA) and polydeoxyribonucleic acid (DNA), both of which may be single-stranded or double-  
30 stranded. DNA includes cDNA, genomic DNA, synthetic DNA, and semi-synthetic DNA. The sequence of nucleotides that encodes a protein is called the sense sequence.

An "exogenous nucleic acid" is genetic material which has been introduced into a cell not naturally containing the nucleic acid sequence.

"Regulatory region" means a nucleic acid sequence which regulates the expression of a second nucleic acid sequence. A regulatory region may include sequences which are naturally responsible for expressing a particular nucleic acid (a homologous region) or may include sequences of a different origin (responsible for expressing different proteins or even synthetic proteins). In particular, the sequences can be sequences of eukaryotic or viral genes or derived sequences which stimulate or repress transcription of a gene in a specific or non-specific manner and in an inducible or non-inducible manner. Regulatory regions include origins of replication, RNA splice sites, enhancers, transcriptional termination sequences, signal sequences which direct the polypeptide into the secretory pathways of the target cell, and promoters.

A regulatory region from a "heterologous source" is a regulatory region which is not naturally associated with the expressed nucleic acid. Included among the heterologous regulatory regions are regulatory regions from a different species, regulatory regions from a different gene, hybrid regulatory sequences, and regulatory sequences which do not occur in nature, but which are designed by one having ordinary skill in the art.

A "vector" is any means for the transfer of a nucleic acid of interest into a host cell. The term "vector" includes both viral and nonviral means for introducing the nucleic acid into a cell *in vitro*, *ex vivo* or *in vivo*. Non-viral vectors include plasmids, liposomes, electrically charged lipids (cytofectins), DNA-protein complexes, and biopolymers. Viral vectors include retrovirus, adeno-associated virus, pox, baculovirus, vaccinia, herpes simplex, Epstein-Barr and adenovirus vectors. A nucleic acid may contain one or more regulatory regions, and/or selectable markers useful in selecting, measuring, and monitoring nucleic acid transfer results (transfer to which tissues, duration of expression, etc.).

"Pharmaceutically acceptable carrier" includes diluents and fillers which are pharmaceutically acceptable for methods of administration, are sterile, and may be aqueous or oleaginous suspensions formulated using suitable dispersing or wetting agents and suspending agents. The particular pharmaceutically acceptable carrier and the ratio of active compound to carrier are determined by the solubility and chemical

properties of the composition, the particular mode of administration, and standard pharmaceutical practice.

### Astrocytes

5           One aspect of the present invention is to provide a population of essentially pure human astrocyte cells. The purified cells may contain introduced genetic material encoding a product of interest. Another aspect of the instant invention is to provide human adult astrocytes having desired therapeutic properties, and suitable for *ex vivo* cell therapy. Transplantation of genetically modified human cells to rat brain is  
10       disclosed in Sabate et al. (Nature Genetics, Volume 9, pp. 256-260 (1995)), the entire contents of which are incorporated herein by reference.

          The present invention now provides a very efficient way to obtain high purity adult human astrocytes, capable of producing factors with biological effect, such as neuroactive substances for *ex vivo* gene therapy. The inventors have now found  
15       conditions that enable successful purification, amplification, and *in vitro* modification of these cells. Substantial levels of gene expression were obtained in cells modified with a recombinant adenovirus. Genetically modified astrocytes enables gene therapy of neurodegenerative diseases and of trauma to the CNS.

          The combination of gene transfer techniques and cell transplantation provides an  
20       approach to deliver therapeutic molecules into the CNS. Astrocytes are particularly well suited for CNS therapy because of their CNS origin, their efficient secretory mechanisms and their role as neuronal support. Most importantly, the use of human adult astrocytes as cellular vehicles for *ex vivo* gene transfer opens the way to autologous transplantation, thus obviating immunological rejection and the side effects of immunosuppressors. As  
25       provided herein, these cells can be purified, expanded and genetically modified *in vitro*. Astrocytes derived from human adult cerebral cortex have been grown and maintained *in vitro* as pure primary cultures for at least 10 months. In addition, cells are efficiently transduced by viral vectors encoding a neuroactive substance. When the neuroactive substance is human tyrosine hydroxylase (hTH) under the negative control of the  
30       tetracycline-based regulatory system (tet-off), the infected cells synthesize large amounts of active hTH and release L-Dopa. In addition, doxycycline, a potent analog of tetracycline, efficiently regulates transgene expression.

### Vectors

As discussed above, a "vector" is any means for the transfer of a nucleic acid according to the invention into a host cell. Preferred vectors are viral vectors, such as retroviruses, herpes viruses, adenoviruses, and adeno-associated viruses. Thus, a gene comprising a nucleic acid of interest is introduced *in vivo*, *ex vivo*, or *in vitro* using a viral vector or through direct introduction of DNA. Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both.

Viral vectors commonly used for *in vivo* or *ex vivo* targeting and therapy procedures are DNA-based vectors and retroviral vectors. Methods for constructing and using viral vectors are known in the art [see, e.g., Miller and Rosman, *BioTechniques* 7:980-990 (1992)]. Preferably, the viral vectors are replication defective, that is, they are unable to replicate autonomously in the target cell. In general, the genome of the replication defective viral vectors which are used within the scope of the present invention lack at least one region which is necessary for the replication of the virus in the infected cell. These regions can either be eliminated (in whole or in part), be rendered non-functional by any technique known to a person skilled in the art. These techniques include the total removal, substitution (by other sequences, in particular by the inserted nucleic acid), partial deletion or addition of one or more bases to an essential (for replication) region. Such techniques may be performed *in vitro* (on the isolated DNA) or *in situ*, using the techniques of genetic manipulation or by treatment with mutagenic agents. Preferably, the replication defective virus retains the sequences of its genome which are necessary for encapsulating the viral particles.

DNA viral vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), vaccinia virus, and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. Defective virus is not replication competent after introduction into a cell, and thus does not lead to a productive viral infection. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Thus, a specific tissue can be specifically targeted. Examples of particular vectors include, but are not limited to, a

defective herpes virus 1 (HSV1) vector [Kaplitt et al., *Molec. Cell. Neurosci.* 2:320-330 (1991)], defective herpes virus vector lacking a glyco-protein L gene [Patent Publication RD 371005 A], or other defective herpes virus vectors [International Patent Publication No. WO 94/21807, published September 29, 1994; International Patent Publication No. WO 92/05263, published April 2, 1994]; an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al. [*J. Clin. Invest.* 90:626-630 (1992); *see also* La Salle et al., *Science* 259:988-990 (1993)]; and a defective adeno-associated virus vector [Samulski et al., *J. Virol.* 61:3096-3101 (1987); Samulski et al., *J. Virol.* 63:3822-3828 (1989); Lebkowski et al., *Mol. Cell. Biol.* 8:3988-3996 (1988)].

Preferably, for *in vivo* administration, an appropriate immunosuppressive treatment is employed in conjunction with the viral vector, *e.g.*, adenovirus vector, to avoid immunodeactivation of the viral vector and transfected cells. For example, immunosuppressive cytokines, such as interleukin-12 (IL-12), interferon- $\gamma$  (IFN- $\gamma$ ), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors [*see, e.g.*, Wilson, *Nature Medicine* (1995)]. In addition, it is advantageous to employ a viral vector that is engineered to express a minimal number of antigens.

Naturally, the invention contemplates delivery of a vector to astrocytes that will express a therapeutically effective amount of a gene of interest for gene therapy applications. The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host.

Any vector, viral or non-viral, of the invention will preferably be introduced *ex vivo* to astrocytes in a pharmaceutically acceptable vehicle or carrier. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in

humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

#### *Adenovirus vectors*

In a preferred embodiment, the vector is an adenovirus vector. Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of the invention to a variety of cell types. Various serotypes of adenovirus exist. Of these serotypes, preference is given, within the scope of the present invention, to using type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see WO94/26914). Those adenoviruses of animal origin which can be used within the scope of the present invention include adenoviruses of canine, bovine, murine (example: Mav1, Beard et al., Virology 75 (1990) 81), ovine, porcine, avian, and simian (example: SAV) origin. Preferably, the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus (e.g. Manhattan or A26/61 strain (ATCC VR-800), for example).

Preferably, the replication defective adenoviral vectors of the invention comprise the ITRs, an encapsidation sequence and the nucleic acid of interest. Still more preferably, at least the E1 region of the adenoviral vector is non-functional. The deletion in the E1 region preferably extends from nucleotides 455 to 3329 in the sequence of the Ad5 adenovirus (PvuII-BglII fragment) or 382 to 3446 (HinfII-Sau3A fragment). Other regions may also be modified, in particular the E3 region (WO95/02697), the E2 region (WO94/28938), the E4 region (WO94/28152, WO94/12649 and WO95/02697), or in any of the late genes L1-L5.

In a preferred embodiment, the adenoviral vector has a deletion in the E1 region (Ad 1.0). Examples of E1-deleted adenoviruses are disclosed in EP 185,573, the contents of which are incorporated herein by reference. In another preferred embodiment, the adenoviral vector has a deletion in the E1 and E4 regions (Ad 3.0). Examples of E1/E4-deleted adenoviruses are disclosed in WO95/02697 and WO96/22378, the contents of which are incorporated herein by reference. In still another preferred embodiment, the adenoviral

vector has a deletion in the E1 region into which the E4 region and the nucleic acid sequence are inserted (see FR94 13355, the contents of which are incorporated herein by reference).

The replication defective recombinant adenoviruses according to the invention can be prepared by any technique known to the person skilled in the art (Levrero et al., Gene 101 (1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917). In particular, they can be prepared by homologous recombination between an adenovirus and a plasmid which carries, inter alia, the DNA sequence of interest. The homologous recombination is effected following cotransfection of the adenovirus and plasmid into an appropriate cell line. The cell line which is employed should preferably (i) be transformable by the said elements, and (ii) contain the sequences which are able to complement the part of the genome of the replication defective adenovirus, preferably in integrated form in order to avoid the risks of recombination. Examples of cell lines which may be used are the human embryonic kidney cell line 293 (Graham et al., J. Gen. Virol. 36 (1977) 59) which contains the left-hand portion of the genome of an Ad5 adenovirus (12%) integrated into its genome, and cell lines which are able to complement the E1 and E4 functions, as described in applications WO94/26914 and WO95/02697. Recombinant adenoviruses are recovered and purified using standard molecular biological techniques, which are well known to one of ordinary skill in the art.

#### *Adeno-associated virus vectors*

The adeno-associated viruses (AAV) are DNA viruses of relatively small size which can integrate, in a stable and site-specific manner, into the genome of the cells which they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies. The AAV genome has been cloned, sequenced and characterised. It encompasses approximately 4700 bases and contains an inverted terminal repeat (ITR) region of approximately 145 bases at each end, which serves as an origin of replication for the virus. The remainder of the genome is divided into two essential regions which carry the encapsulation functions: the left-hand part of the genome, which contains the rep gene involved in viral replication and expression of the viral genes; and the right-hand part of the genome, which contains the cap gene encoding the capsid proteins of the virus.

The use of vectors derived from the AAVs for transferring genes *in vitro* and *in vivo* has been described (see WO 91/18088; WO 93/09239; US 4,797,368, US 5,139,941, EP 488

528). These publications describe various AAV-derived constructs in which the rep and/or cap genes are deleted and replaced by a gene of interest, and the use of these constructs for transferring the said gene of interest in vitro (into cultured cells) or in vivo, (directly into an organism). The replication defective recombinant AAVs according to the invention can be prepared by cotransfecting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsulation genes (rep and cap genes), into a cell line which is infected with a human helper virus (for example an adenovirus). The AAV recombinants which are produced are then purified by standard techniques.

The invention also relates, therefore, to an AAV-derived recombinant virus whose genome encompasses a sequence encoding a nucleic acid of interest flanked by the AAV ITRs. The invention also relates to a plasmid encompassing a sequence encoding a nucleic acid encoding an anti-angiogenic factor flanked by two ITRs from an AAV. Such a plasmid can be used as it is for transferring the nucleic acid sequence, with the plasmid, where appropriate, being incorporated into a liposomal vector (pseudo-virus).

#### *Retrovirus vectors*

In another embodiment the gene can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al., 1983, Cell 33:153; Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No. 4,980,289; Markowitz et al., 1988, J. Virol. 62:1120; Temin et al., U.S. Patent No. 5,124,263; EP 453242, EP178220; Bernstein et al. Genet. Eng. 7 (1985) 235; McCormick, BioTechnology 3 (1985) 689; International Patent Publication No. WO 95/07358, published March 16, 1995, by Dougherty et al.; and Kuo et al., 1993, Blood 82:845. The retroviruses are integrating viruses which infect dividing cells. The retrovirus genome includes two LTRs, an encapsulation sequence and three coding regions (gag, pol and env). In recombinant retroviral vectors, the gag, pol and env genes are generally deleted, in whole or in part, and replaced with a heterologous nucleic acid sequence of interest. These vectors can be constructed from different types of retrovirus, such as, HIV, MoMuLV ("murine Moloney leukaemia virus" MSV ("murine Moloney sarcoma virus"), HaSV ("Harvey sarcoma virus"); SNV ("spleen necrosis virus"); RSV ("Rous sarcoma virus") and Friend virus. Defective retroviral vectors are disclosed in WO95/02697.

In general, in order to construct recombinant retroviruses containing a nucleic acid sequence, a plasmid is constructed which contains the LTRs, the encapsulation sequence and the coding sequence. This construct is used to transfect a packaging cell line, which cell line is able to supply in trans the retroviral functions which are deficient in the plasmid. In general, the packaging cell lines are thus able to express the gag, pol and env genes. Such packaging cell lines have been described in the prior art, in particular the cell line PA317 (US4,861,719); the PsiCRIP cell line (WO90/02806) and the GP+envAm-12 cell line (WO89/07150). In addition, the recombinant retroviral vectors can contain modifications within the LTRs for suppressing transcriptional activity as well as extensive encapsulation sequences which may include a part of the gag gene (Bender et al., J. Virol. 61 (1987) 1639). Recombinant retroviral vectors are purified by standard techniques known to those having ordinary skill in the art.

Retroviral vectors can be constructed to function as infectious particles or to undergo a single round of transfection. In the former case, the virus is modified to retain all of its genes except for those responsible for oncogenic transformation properties, and to express the heterologous gene. Non-infectious viral vectors are prepared to destroy the viral packaging signal, but retain the structural genes required to package the co-introduced virus engineered to contain the heterologous gene and the packaging signals. Thus, the viral particles that are produced are not capable of producing additional virus.

Targeted gene delivery is described in International Patent Publication WO 95/28494, published October 1995.

#### Non-viral vectors

Alternatively, the vector can be introduced to astrocytes by lipofection. For the past decade, there has been increasing use of liposomes for encapsulation and transfection of nucleic acids *in vitro*. Synthetic cationic lipids designed to limit the difficulties and dangers encountered with liposome mediated transfection can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker [Felgner, et. al., *Proc. Natl. Acad. Sci. U.S.A.* 84:7413-7417 (1987); see Mackey, et al., *Proc. Natl. Acad. Sci. U.S.A.* 85:8027-8031 (1988); Ulmer et al., *Science* 259:1745-1748 (1993)]. The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes [Felgner and Ringold, *Science* 337:387-388 (1989)]. Particularly useful lipid compounds and compositions for transfer of nucleic acids are described in

International Patent Publications WO95/18863 and WO96/17823, and in U.S. Patent No. 5,459,127. The use of lipofection to introduce exogenous genes into specific cells *ex vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. Lipids may be chemically coupled to other molecules for the purpose of targeting [see Mackey, et. al., *supra*]. Targeted peptides, *e.g.*, hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.

Other molecules are also useful for facilitating transfection of a nucleic acid, such as a cationic oligopeptide (*e.g.*, International Patent Publication WO95/21931), peptides derived from DNA binding proteins (*e.g.*, International Patent Publication WO96/25508), or a cationic polymer (*e.g.*, International Patent Publication WO95/21931).

It is also possible to introduce the vector as a naked DNA plasmid. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter [see, *e.g.*, Wu et al., *J. Biol. Chem.* 267:963-967 (1992); Wu and Wu, *J. Biol. Chem.* 263:14621-14624 (1988); Hartmut et al., Canadian Patent Application No. 2,012,311, filed March 15, 1990; Williams et al., *Proc. Natl. Acad. Sci. USA* 88:2726-2730 (1991)]. Receptor-mediated DNA delivery approaches can also be used [Curiel et al., *Hum. Gene Ther.* 3:147-154 (1992); Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)].

### Nucleic Acids

Genetic modification and grafting of astrocytes enables their use in numerous applications, depending on the introduced genetic material.

Reporter genes, such as the *Lac Z* gene, may help to solve important scientific questions in the field of neural development. In particular, the potential of progenitors explanted from various zones of the brain to survive and differentiate independently of their origin could be investigated by following them after grafting in various zones of developing or adult brains.

Nucleic acids comprising a therapeutic gene are of particular interest. These genes include any gene encoding a neuroactive substance; a substance capable of

exerting a beneficial effect on cells of the central nervous system. It may be a substance capable of compensating for a deficiency in or of reducing an excess of an endogenous substance. Alternatively, it may be a substance conferring new properties on the cells.

5 The neuroactive substance may be an antisense sequence, a polypeptide or a protein. Among the polypeptides and proteins suitable for practice of the invention are growth factors, neurotrophic factors, cytokines, neurotransmitters, enzymes, neurotransmitter receptors and hormone receptors.

Preferably, the growth factor is a colony stimulating factor (G-CSF, GM-CSF, M-CSF, CSF, and the like), endothelial cell growth factor (ECGF, FGF1), fibroblast  
10 growth factor (aFGFa, bFGF) or vascular cell growth factor (VEGF). Among the neurotrophic factors, the preferred factors are ciliary neurotrophic factor (CNTF), glial cell maturation factors (GMFa, b), GDNF, BDNF, NT-3, NT-5 and the like. The complete nucleotide sequence encoding NT-3 is disclosed in WO91/03569, the contents of which are incorporated herein by reference.

15 Preferred cytokines are the interleukins and interferons. Enzymes included within the scope of the invention are the enzymes for the biosynthesis of neurotransmitters (tyrosine hydroxylase, acetylcholine transferase, glutamic acid decarboxylase) and the lysosomal enzymes (hexosaminidases, arylsulphatase, glucocerebrosidase, HGPRT). The enzymes involved in the detoxification of free  
20 radicals (super oxide dismutase I, II or III, catalase, glutathione peroxidase) are preferred. Receptors include the androgen receptors (involved in Kennedy's disease).

These proteins may be used in native form, or in the form of a variant or fragment thereof.

The neuroactive substance may also be an antisense sequence. The down  
25 regulation of gene expression using antisense nucleic acids can be achieved at the translational or transcriptional level. Antisense nucleic acids of the invention are preferably nucleic acid fragments capable of specifically hybridizing with a nucleic acid encoding an endogenous neuroactive substance or the corresponding messenger RNA. These antisense nucleic acids can be synthetic oligonucleotides, optionally modified to  
30 improve their stability and selectivity. They can also be DNA sequences whose expression in the cell produces RNA complementary to all or part of the mRNA encoding an endogenous neuroactive substance. Antisense nucleic acids can be prepared

by expression of all or part of a nucleic acid encoding an endogenous neuroactive substance, in the opposite orientation, as described in EP 140308. Any length of antisense sequence is suitable for practice of the invention so long as it is capable of down-regulating or blocking expression of the endogenous neuroactive substance.

- 5 Preferably, the antisense sequence is at least 20 nucleotides in length. The preparation and use of antisense nucleic acids, DNA encoding antisense RNAs and the use of oligo and genetic antisense is disclosed in WO92/15680, the contents of which are incorporated herein by reference.

- The nucleic acid may be of natural or artificial origin. It may be especially  
10 genomic DNA (gDNA), complementary DNA (cDNA), hybrid sequences or synthetic or semisynthetic sequences. It may be of human, animal, plant, bacterial or viral origin and the like. It may be obtained by any technique known to persons skilled in the art, and especially by screening libraries, by chemical synthesis, or alternatively by mixed methods including chemical or enzymatic modification of sequences obtained by  
15 screening libraries. It is preferably cDNA or gDNA.

More preferred therapeutic products include in the case of Parkinson's disease the cDNA encoding tyrosine hydroxylase (TH) or a neurotrophic factor such as BDNF (brain derived neurotrophic factor) which favor the survival of dopaminergic neurons.

- Similarly, for Alzheimer's disease, the cDNA encoding choline acetyl  
20 transferase and/or NGF (nerve growth factor) could prevent degeneration of cholinergic neurons.

Recent findings suggest that neurotrophic factors like BDNF and GDNF can be trophic factors for dopaminergic cells. Introduction into astrocytes of genetic material encoding neurotrophic factors are expected to improve graft survival.

- 25 Several adenovirus vectors encoding therapeutic genes have now been constructed. For instance, an adenovirus encoding tyrosine hydroxylase (TH) has been constructed. The grafting of *in vitro* infected astrocytes according to the invention constitutes a very efficient way to deliver therapeutic amounts of TH in the brain. Other adenovirus-derived vectors encoding therapeutic genes include Ad-aFGF, Ad-bFGF, Ad-  
30 GDNF, Ad-GAD.

The genetic material of interest can also be an antisense-RNA or ribozyme or a DNA molecule encoding said antisense-RNA or ribozyme. These products are of

particular interest for inhibiting production of toxic proteins such as  $\beta$ -amyloid precursor, TAU proteins, etc.

Preferably, the genetic material is a DNA encoding a protein or peptide of interest. As indicated above, said protein or peptide is preferably a neuroactive substance  
5 such as a growth factor (i.e. a cytokine) a neurotrophic factor, an enzyme or a neurotransmitter.

In an other embodiment, the genetic material is a DNA encoding an antisense-RNA or a ribozyme

#### 10 **Regulatory Regions**

Generally, the nucleic acids of the present invention are linked to one or more regulatory regions. Said regions can include a regulatable or inducible promoter; neural cell-specific promoter, or viral promoter. Selection of the appropriate regulatory region or regions is a routine matter, within the level of ordinary skill in the art.

15 The regulatory regions may comprise a promoter region for functional transcription in astrocytes, as well as a region situated in 3' of the gene of interest, and which specifies a signal for termination of transcription and a polyadenylation site. All these elements constitute an expression cassette.

Promoters that may be used in the present invention include both constitutive  
20 promoters and regulated (inducible) promoters. The promoter may be naturally responsible for the expression of the nucleic acid. It may also be from a heterologous source. In particular, it may be promoter sequences of eucaryotic or viral genes. For example, it may be promoter sequences derived from the genome of the cell which it is desired to infect. Likewise, it may be promoter sequences derived from the genome of a  
25 virus, including the adenovirus used. In this regard, there may be mentioned, for example, the adenovirus E1A or major late promoter (MLP), a cytomegalovirus (CMV) promoter or a Rous Sarcoma Virus (RSV) promoter.

In addition, the promoter may be modified by addition of activating or regulatory sequences or sequences allowing a tissue-specific or predominant expression (enolase  
30 and GFAP promoters and the like). Moreover, when the nucleic acid does not contain promoter sequences, it may be inserted, such as into the virus genome downstream of such a sequence.

Some promoters useful for practice of this invention are ubiquitous promoters (e.g. HPRT, vimentin, actin, tubulin), intermediate filament promoters (e.g. desmin, neurofilaments, keratin, GFAP), therapeutic gene promoters (e.g. MDR type, CFTR, factor VIII), tissue-specific promoters (e.g. actin promoter in smooth muscle cells),  
5 promoters which are preferentially activated in dividing cells, promoters which respond to a stimulus (e.g. steroid hormone receptor, retinoic acid receptor), tetracycline-regulated transcriptional modulators, cytomegalovirus immediate-early, retroviral LTR, metallothionein, SV-40, E1a, and MLP promoters. Tetracycline-regulated transcriptional modulators and CMV promoters are described in WO 96/01313, US  
10 5,168,062 and 5,385,839, the contents of which are incorporated herein by reference.

#### Pharmaceutical Administration

15 The present invention enables purification and amplification of adult human astrocytes, and their use for the successful delivery of genes *in vitro* with high efficiency. These cells can then be administered to the CNS of recipient organisms. The invention thereby provides important clinical and scientific applications, such as treatment of trauma to the CNS and of neurodegenerative disorders.

20 The process according to the present invention enables one to target precisely a particular region of the CNS, such as a site within the brain, depending on the transferred therapeutic gene and the disorder to be treated. Thus, according to the site of the impairment to be treated, the administration is made into sites of the brain including, for instance, the striatum, hippocampus or substantia nigra. Preferably, they are grafted in  
25 the striatum.

According to the present invention, it is now possible, by stereotactic injection, to deliver astrocytes for engraftment. Determination of the coordinates for administration would be based on the disorder to be treated, and would be determined by the skilled practitioner. The actual therapeutic regimen, including site of injection(s), number and  
30 schedule of injections, and particular dosage(s), would also be determined by the skilled practitioner. In general, the number of cells engrafted at a site will be between  $1 \times 10^3$  and  $1 \times 10^{10}$ , preferably  $1 \times 10^3$  to  $1 \times 10^9$ , and more preferably  $1 \times 10^6$  to  $1 \times 10^8$ .

It is also an object of the invention to provide an implant comprising astrocyte cells as described above. Preferably, the implant contains non-cellular material increasing survival and in vivo proliferation and differentiation of the cells. The implant can contain for instance collagen, gelatin, fibronectin, lectins, bio-compatible supports such as bone or polytetrafluoroethylen fibers, etc). The invention also concerns a method for the delivery of a therapeutic product to the CNS of a recipient comprising grafting into the brain of said recipient genetically-modified human astrocytes containing introduced genetic material encoding said therapeutic product.

The invention provides safe, non toxic, long term expression of therapeutic genes in vivo. The invention is of particular interest in the treatment of neurodegenerative disorders such as neuropathies, strokes, spinal cord injury, amyotrophic lateral sclerosis, Huntington's chorea, Alzheimer's and Parkinson's diseases, cerebral palsy, epilepsy, lysosomal diseases (e.g. Tay Sachs and Sandhoff diseases, metachromatic leucodystrophy, Gaucher's disease, mucopolysaccharidosis, Lesh Nyhan, etc) as well as brain tumours.

The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention.

### Examples

The present invention will be described in greater detail with the aid of the following examples which should be considered as illustrative and nonlimiting. Example 1 describes a cell culture protocol enabling the recovery of long-term, pure primary cultures of human adult astrocytes. Example 2 demonstrates that these cells can be genetically modified by using an adenoviral vector encoding human tyrosine hydroxylase (TH) under the control of the tetracycline-based (tet-off) regulatory system (Gossen and Bujard, 1992). TH is the rate limiting enzyme for the synthesis of catecholamines, by converting tyrosine to L-Dopa. Several studies have demonstrated its therapeutic potential in animal model of Parkinson's disease (Wolff et al., 1989;

Horellou et al., 1990a,b; Fisher et al., 1991). Infected cells produced large amounts of active hTH in the absence of doxycycline, a potent analog of tetracycline.

### **General Molecular Biology**

- 5 In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein
- 10 "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* [B.D. Hames & S.J. Higgins eds. (1985)]; *Transcription And Translation* [B.D. Hames & S.J. Higgins, eds. (1984)]; *Animal Cell Culture* [R.I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical*
- 15 *Guide To Molecular Cloning* (1984); F.M. Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

### ***Example 1: Explantation and characterization of primary cultured human adult astrocytes***

#### **20 1.1 Cell culture**

- Adult human tissue was isolated from the cerebral cortex of patients (average age 51.5±16.8 years old) undergoing surgical resections, with the consent of the patient, according to the policy of the hospital. Immediately after surgery, the tissue was mechanically dissociated and centrifuged in DMEM/F12 (Sigma) containing D-glucose
- 25 (3.15 g/l), HEPES (3.57 g/l), sodium bicarbonate (1.2 g/l), and supplemented with 10% fetal calf serum (FCS, Seromed), 2 mM glutamine (Gibco), antibiotics (penicillin/streptomycin mix, 100 µg/ml, Gibco) and fungizone (Gibco), pH 7.4. The pellet was resuspended in the same medium and plated in a 5 cm culture flask (Costar). Cultures were maintained at 37°C in a humidified atmosphere containing 10% CO<sub>2</sub>.
- 30 Forty-eight hours later, the medium was changed. These primary cultures were maintained by changing the medium once a week thereafter.

As freezing/thawing procedures, confluent cells were harvested with 0.25% trypsin and 0.2% EDTA (Gibco) and rapidly washed with phosphate buffered saline (PBS, 0.1 M, pH 7.4) to remove the medium-containing serum. The cells were then frozen first at -20°C and finally stored at -80°C in DMEM/F12 supplemented with 10% dimethylsulfoxide (DMSO, Sigma). Cells were thawed by placing the vial in a water bath at 40°C for 2-4 minutes. and replated in a Costa culture flask. Forty-eight hours later, the medium was replaced to eliminate DMSO.

### 1.2 *Assessment of cell proliferation*

Two different methods were used: direct counting under phase-contrast in a predetermined area of 2 mm<sup>2</sup> and GFAP-bromodeoxyuridine labeling (BrdU, an analog of thymidine which is only incorporated into replicating DNA) revealed with a double immunofluorescence protocol. Primary cultured cells were plated onto NUNC™ Petri dishes (60x15 mm) with grids (2 mm<sup>2</sup>) in DMEM/F12.

The proliferation rate was determined under various culture conditions: (a) without FCS, (b) with 10% FCS, (b) 20% FCS, (c) 10% FCS and 5% horse serum (HS), (d) 10% FCS and 10% HS, (e) NGF (50 ng/ml, Sigma), (f) bFGF (50 ng/ml, Boehringer-Mannheim). For proliferation experiments, the medium was changed twice a week. All cultures were counted every 10 hours for 80 hours. The activity of the NGF and bFGF used was ascertained by bioassay: the neuritic extension of PC12 cells (cultured on polyornithine-coated dishes in RPMI supplemented with 10% HS and 5% FCS) exposed to NGF (50 ng/ml), and the differentiation of neuroepithelial progenitor cells in the presence of bFGF (10 ng/ml in DMEM/HAMF12 (see refs in Sabate et al., 1995).

For BrdU incorporation experiments. BrdU was added to primary cultures 2 days post-plating. Cultures were incubated in the presence of 5 or 10 µM BrdU for 4 days. The BrdU treatment was performed simultaneously on 3T3 and 293 cells as proliferation controls. The positive cells were detected by immunocytochemistry, as indicated below.

### 1.3 *Immunocytochemical procedures*

Cells in primary cultures were rapidly rinsed in PBS, incubated in a fixative solution (4% paraformaldehyde in PBS) for 10 min at room temperature. After rinses in PBS, the cells were treated with a blocking solution (10% goat serum and 0.2% Triton

X-100 in PBS) for 30 min at room temperature, and then incubated with the primary polyclonal antibody (GFAP, Dakopatts, 1:100; S100 $\beta$ , Sigma, diluted 1:100; TH, Inst. J. Boy, diluted 1:200; BrdU, Jackson, 1:50; OX42, Cedarlane, 1:200) containing 5% goat serum and 0.1% Triton X-100 in PBS.

- 5 For BrdU immunodetection, the cells were first denatured in 2N HCl for 20 min, at room temperature. After neutralization in 0.1N sodium borate for 10 min, the samples were rinsed in PBS and processed as described for GFAP immunocytochemistry.

#### 1.4 Characterization of cultured astrocytes

- 10 To assess the potential of human adult astrocytes for autologous transplantation into the CNS, it was first necessary to test whether these cells can be maintained as primary cultures. Previous studies reported that primary cultures of human adult astrocytes were enriched in microglial cells (Yong et al., 1991, 1992). The composition of the medium and the times between tissue resection, dissociation and cell seeding were
- 15 varied in order to optimize the culture procedures to obtain astrocyte-enriched preparations. DMEM supplemented with serum is an appropriate culture medium for rodent astroglial cultures. Enriched DMEM supplemented with fetal calf serum (FCS) and with HAM/F12 nutrients was used for astrocyte cultures. The first cells to attach to the culture dish after dissociation and seeding are astrocytes. Various lag times (24-120
- 20 hours) until the first change of medium containing unattached and/or dead cells and cell debris were tested. A 48 hour (2 days) delay was optimal for obtaining essentially pure astroglial cultures. Surprisingly, microglial cells do not attach to the culture dish under these conditions.

- After two days in DMEM/F12 supplemented with 10% FCS, cells were flattened
- 25 in the culture dish. Although cell morphology depended on culture confluence, the large majority of cells exhibited a flat polygonal morphology (Figures 1A-B). The flattened cells were identified by immunodetection of astroglial markers including GFAP, the major gliofilament protein, and S100 $\beta$ , a cytoplasmic calcium-binding protein (Figure 2). Virtually all the primary cultured cells were GFAP- (Figure 2A) and S100 $\beta$ -positive
- 30 (Figure 2B). The presence of microglial cells in the cultures was tested by OX42 immunostaining and labeling with B<sub>4</sub> isolectin from *Griffonia simplicifolia*, which is used as a specific marker for microglial cells (Streit, 1990). No staining was observed,

confirming the presence of a culture of astrocytes essentially free of microglial cells. Taken together, these results show that the present invention provides an essentially pure culture of human adult astrocytes. Microscopic inspection of the cultures revealed that many GFAP-positive cells were in mitosis (Figure 1B).

5

#### 1.4.1 *In vitro* proliferation of human adult astrocytes

Preliminary observations indicated that without FCS, none or few of the cultured cells were dividing, whereas mitotic profiles were often observed when 10% FCS was added to the DMEMF12 medium. Double immunofluorescent labeling of GFAP and BrdU revealed that the dividing cells were astrocytes. The capacity of primary cultured human adult astrocytes to proliferate in various culture conditions was analyzed. Soluble molecules including the trophic factors NGF and bFGF, and serum of various species have mitogenic properties on cultured rodent and human fetal astrocytes (see refs in Yong et al., 1991, 1992, and Stachowiak et al., 1997). The effects of various combinations, including FCS, HS, bFGF and NGF, on cell proliferation was tested: 0, 10 and 20% FCS, 10% FCS supplemented with 5 or 10% HS, DMEM supplemented with 50 ng/ml bFGF, DMEM supplemented with 50 ng/ml NGF (Figures 3A-B). Twelve hours after seeding in the presence of FCS, the cells attached and flattened onto the dish surface. Cells only proliferated in the presence of FCS (Figure 3A), and proliferation was maximum at 20% FCS. When cultured in the presence of 10% or 20 % FCS, the astroglial population doubled in 40 hours and 20 hours respectively (Figure 3A). The rate of cell proliferation in the presence of 20% FCS is suitable for cell transplantation, enabling the recovery of  $1-5 \times 10^6$  human adult astrocytes within one month from a single biopsy.

Surprisingly, the addition of NGF or bFGF (50 ng/ml medium) did not accelerate the proliferation of human adult astrocytes (Figure 3B). When cultured with FCS supplemented with 5 or 10% HS, most of the human adult astrocytes did not attach to the culture dish and remained in the medium. Nevertheless, a few spherical cells attached but did not flatten onto the culture dish. From 3 days post-plating, some of the attached cells flattened and proliferated very slowly (Figure 3B). In summary, human adult astrocytes can be expanded *in vitro* in the presence of FCS. Twenty percent FCS enables the recovery of a large number of cells suitable for cell transplantation.

30

#### 1.4.2 Cell characterization following freezing/thawing procedures

A patient may receive more than one transplant. Therefore, one issue in the development of autologous grafting in humans is the cryopreservation of primary cultured astrocytes from a single biopsy. Human adult astroglial cells were tested for growth after freezing/thawing procedures. At the first passage, corresponding to 3-4 weeks *in vitro* in DMEM/F12 supplemented with 10% FCS, cultured cells were frozen and kept at -80°C for 2-6 months. Then, cells were rapidly thawed and seeded in DMEM/F12 supplemented with 10% FCS. Cells were carefully observed daily. Ten hours after thawing and seeding, the cells attached and flattened onto the culture dish. They exhibited similar morphological and immunocytochemical features as cells which had not been subjected to freezing procedures. GFAP and S100 $\beta$  immunostaining confirmed that these cells conserved their astroglial phenotype. During the first day post-plating, the cells did not proliferate. Between day 2 and day 3, the first mitotic profiles were observed. Then, the cell expansion accelerated, and the mean division time was 60 hours in the presence of 10% FCS (Figure 3A). Therefore, human adult astrocytes obtained according to the present invention maintain their capacity to divide following freezing/thawing procedures.

#### Example 2. Genetic modification of cultured astrocytes

##### 2.1. Adenoviral vectors

25

Adenoviral vectors represent efficient tools to transfer foreign genes to nerve cells as shown by recent studies where direct intracerebral injection to rodent brain provides gene therapy of the central nervous system (WO94/08026). In order to amplify the number of cells suitable for grafting, the inventors have demonstrated that recombinant adenoviruses can efficiently allow gene transfer to cultured human astrocytes.

30

Many Adenovirus-derived vectors have been disclosed in the literature and can be prepared by one skilled in the art. Such vectors can be used in the present invention. (see in particular EP 185 573, Perricaudet et al., FEBS Letters 267 (1990) 60; Levrero et al, Gene 101 (1991) 195, FR 9305954, FR9308596, WO94/12649). An Ad.RSV $\beta$ gal vector has previously been disclosed in the literature. See for example Stratford-Perricaudet et al. (*J.Clin.Invest.* 90, 626-630 (1992)). This vector contains the E.coli LacZ gene inserted in an adenovirus Ad5 deleted for the E1 and E3 regions.

## 2.2 *Infection of human adult astrocytes with AdPGKtet hTH-1*

Cells were seeded on 6 well culture plates at a density of  $6 \times 10^4$  cells/well in DMEM/F12 without serum (FCS). Then, the cells were incubated for 4-6 hours with AdPGKtet hTH-1, in which a human tyrosine hydroxylase gene (hTH-1) is under the control of the tetracycline-based "tet-off" regulatory system (Gossen and Bujard, 1992). The hTH gene and the transactivator are driven respectively by a minimal CMV and phosphoglycerate kinase (PGK) promoter. Different multiplicities of infection (MOI) were tested (75, 150 and 300 pfu/cells). Doxycycline was added to the culture medium to a final concentration of 10 ng/ml. The medium was renewed every second day.

## 2.3 *Assessment of TH activity and L-Dopa production by transduced human adult astrocytes*

Three, 7 and 14 days after infection, cells were harvested and processed to measure TH activity and evaluate L-Dopa production. TH activity of cell pellets was assayed as previously described (Reinhard et al., 1986). The production of L-Dopa was assessed after growing human astrocytes for 24 h in DMEM/F12 without FCS. Conditioned media was collected, and 0.5 ml aliquots were mixed with an alumina suspension (40 mg/ml) in 0.05 M Tris-HCl, pH 8.6. Each mixture was then continuously stirred for 10 min, washed with the Tris-HCl buffer, and the alumina finally collected by centrifugation (800 g, 5 min, 4°C). Catechols adsorbed onto the alumina gel were eluted with 0.6 N perchloric acid (0.1 ml per sample), and the eluate was neutralized with 2 M

potassium phosphate pH 7.4 (20  $\mu$ l per sample). After centrifugation (30 000 g, 15 min, 4°C), 10  $\mu$ l aliquots of the cleared supernatant were injected into a high performance liquid chromatography column (Ultrasphere IP, 25 cm, 0.46 cm outer diameter, 5  $\mu$ m) for the electrochemical quantification of L-Dopa, as described in detail elsewhere (Adrien et al., 1989).

#### 2.4 *Result of Genetic engineering of human adult astrocytes*

Cultured human adult astrocytes can be modified by a recombinant adenoviral vector. Optimal transduction is obtained by infecting the cells with a viral preparation of 300 pfu/cell for 6 hours. No obvious toxicity was observed. Fifty-60% of the cells were hTH-positive as assessed by immunocytochemistry (Figures 3A-B). An enzymatic assay developed by Reinhard and colleagues (1986) was used to test whether the hTH was active 3, 7 and 14 days post-infection. TH activity was detectable 3 days after infection (1,290 pmol/mg prot/h), and higher on days 7 (19,000 pmol/mg prot/h) and 14 (35,650 pmol/mg prot/h). In addition, HPLC assays showed that TH-transduced human astrocytes produced 1  $\mu$ g L-Dopa /10<sup>6</sup> cells/24 h, 14 days-post-infection.

To test the efficacy of the tetracycline-based regulatory system, the astroglial cultures were treated with doxycycline (10 ng/ml), a potent analog of tetracycline. Doxycycline efficiently reduced TH expression. TH activity was decreased by at least 10 fold in the presence of doxycycline on day 14 (3,590 pmol/mg prot/h in doxycycline-treated cells vs 35,650 pmol/mg prot/h in untreated cultures) (Figure 4). This indicated that the hTH-1 expression was efficiently controlled by doxycycline. However, as shown on Figure 4, in doxycycline-treated astrocytes, the level of TH activity did not return to baseline. This observation suggested that the minimal promoter P\*hCMV, which drives the expression of hTH-1 in the AdPGKtet hTH-1 vector, has a basal activity in the primary cultured human adult astrocytes. Indeed, previous studies report activation of a hCMV promoter in astrocytes under certain experimental conditions, such as after injury, suggesting an environmental regulation of hCMV promoter (McCarthy et al., 1995; Fritschy et al., 1996).

### 2.5 *Use of other vectors*

As indicated above, other types of vectors can be used to genetically modify the  
5 astrocytes according to the invention. This can be viral or non-viral (chemical) vectors.  
Preferred viral vectors include AAV, retroviruses, herpes viruses and vaccinia virus. Non  
viral vectors include Calcium-phosphate precipitation, liposome-mediated transfection,  
cationic lipid transfection and lipopolyamine-mediated transfection.

10

All the references discussed herein are incorporated by reference.

One skilled in the art will readily appreciate the present invention is well adapted  
to carry out the objects and obtain the ends and advantages mentioned, as well as those  
inherent therein. The peptides, polynucleotides, methods, procedures and techniques  
15 described herein are presented as representative of the preferred embodiments, and  
intended to be exemplary and not intended as limitations on the scope of the present  
invention. Changes therein and other uses will occur to those of skill in the art which are  
encompassed within the spirit of the invention or defined by the scope of the appended  
claims.

20

REFERENCES

- ADRIEN, J., LANFUMEY, L., GOZLAN, H., FATTACCINI, C.M., and HAMON, M.  
(1989). Biochemical and electrophysiological evidence for an agonist action of CM  
5 57493 at pre- and post-synaptic 5-HT<sub>1A</sub> receptors in brain. *J. Pharmacol. Exp. Ther.*  
**248**, 1222-1230.
- ALOISI, F., BORSELLINO, G., SAMOGGIA, P., TESTA, U., CHELUCCI, C.,  
RUSSO, G., PESCHLE, C. LEVI, G. (1992). Astrocyte cultures from human  
embryonic brain: characterization and modulation of surface molecules by  
10 inflammatory cytokines. *J. Neurosci. Res.* **32**, 494-506.
- AUBERT, I., RIDET, J.L., and GAGE, F.H. (1995). Regeneration in the adult  
mammalian CNS: guided by development. *Curr. Opin. Neurobiol.* **5**, 625-635.
- BILANG-BLEUEL, A., REVAH, F., COLIN, P., LOCQUET, I., ROBERT, J.J.,  
MALLET, J. and HORELLOU, P. (1997). Intrastriatal injection of an adenoviral  
15 vector expressing GDNF prevents dopaminergic neuron degeneration and behavioral  
impairment in a rat model of Parkinson's disease. *Proc. Natl. Acad. Sci. USA* **94**,  
8818-8823.
- CASTILLO Jr., B., DEL CERRO, M., BREAKFIELD, X.O., FRIM, D.M.,  
BARNSTABLE, C.J., DEAN, D.O., and BOHN, M.C. (1994). Retinal ganglion cell  
20 survival is promoted by genetically modified astrocytes designed to secrete brain-  
derived neurotrophic factor (BDNF). *Brain Res.* **647**, 30-37.
- CORTI, O., HORELLOU, P., COLIN, P., CATTANEO, E., and MALLET, J. (1996).  
Intracerebral tetracycline-dependent regulation of gene expression in grafts of neural  
precursors. *NeuroReport* **7**, 1655-1659.
- 25 CUNNINGHAM, L.A., HANSEN, J.T., SHORT, M.P., and BOHN, M.C. (1991). The  
use of genetically altered astrocytes to provide nerve growth factor (NGF) to adrenal  
chromaffin cell grafted into the striatum. *Brain Res.* **561**, 192-202.
- CUNNINGHAM, L.A., SHORT, M.P., BREAKFIELD, X.O., and BOHN, M.C. (1994).  
Nerve growth factor released by transgenic astrocytes enhanced the function of  
30 adrenal chromaffin cell grafts in a rat model of Parkinson's disease. *Brain Res.* **558**,  
219-223.

- FISHER, L.J., and GAGE, F.H. (1993). Grafting in the mammalian central nervous system. *Physiol. Rev.* **73**, 583-616.
- FISHER, L.J. (1997). Neural precursor cells: applications for the study and repair of the central nervous system. *Neurobiol. Dis.* **4**, 1-22.
- 5 FISHER, L.J., JINNAH, H.A., KALE, L.C., HIGGINS, G.A., and GAGE, F.H. (1991). Survival and function of intrastrially grafted fibroblasts genetically modified to produce L-DOPA. *Neuron* **6**, 371-380.
- FRITSCHY, J.M., BRANDNER, S., AGUZZI, A., KOEDOOD, M., LUSCHER, B., and MITCHELL, P.J. (1996). Brain cell type specificity and gliosis-induced activation of  
10 the human cytomegalovirus immediate-early promoter in transgenic mice. *J. Neurosci.* **16**, 2275-82.
- GAGE, F.H., RAY, J., and FISHER, L.J. (1995). Isolation, characterization and use of stem cells from the CNS. *Ann. Rev. Neurosci.* **18**, 159-192.
- GOODMAN, J.C., TRASK, T.W., CHEN, S.H., WOO, S.L.C, GROSSMAN, R.G.,  
15 CAREY, K.D., HUBBARD, G.B., CARRIER, D.A., RAJAGOPALAN, S., AGUILAR-CORDOVA, E., and SHINE, H.D. (1996). Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies. *Human Gene Ther.* **7**, 1241-1250.
- 20 GOSSEN, M., and BUJARD, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl. Acad. Sci. USA* **89**, 5547-5551.
- GOSSEN, M., FREUNDLIEB, S., BENDER, G., MULLER, G., HILLEN, W., and BUJARD, H. (1995). Transcriptional activation by tetracyclines in mammalian cells.  
25 *Science* **268**, 1766-1769.
- HORELLOU, P., BRUNDIN, P., KALEN, P., MALLET, J., and BJÖRKLUND, A. (1990a). In vivo release of DOPA and dopamine from genetically engineered cells grafted to the denervated striatum. *Neuron* **5**, 393-402.
- HORELLOU, P., MARLIER, L., PRIVAT, A., and MALLET, J. (1990b). Behavioral  
30 effect of engineered cells that synthesize L-Dopa or dopamine after grafting into the rat neostriatum. *Eur. J. Neurosci.* **2**, 116-119.

- HORELLOU, P., VIGNE, E., CASTEL, M.N., BARNEOUD, P., COLIN, P., PERRICAUDET, M., DELAERE, P. and MALLET, J. (1994). Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. *NeuroReport* **6**, 49-53.
- 5 JUORIO, A.V., LI, X.M., WALZ, W., and PATERSON, I.A. (1993). Decarboxylation of L-dopa by cultured mouse astrocytes. *Brain Res.* **626**, 306-309.
- KISTNER, A., GOSSEN, M., ZIMMERMANN, F., JERECIC J., ULLMER, C., LUBBERT, H., and BUJARD, H. (1996). Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. *Proc. Natl. Acad. Sci.*
- 10 USA **93**, 10933-10938.
- KOJIMA, H., ABIRU, Y., SAKAJIRI, K., WATABE, K., OHISHI, N., TAKAMORI, M., HATANAKA, H., and YAGI, K. (1997). Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain.
- 15 Biochem. Biophys. Res. Commun. **238**, 569-573.
- LA GAMMA, E.F., WIESINGER, G., LENN, N.J., and STRECKER, R.E. (1993). Genetically modified primary astrocytes as cellular vehicles for gene therapy in the brain. *Cell Transplant.* **2**, 207-214.
- LEVALLOIS, C., MALLET, J., and PRIVAT, A. (1996). An adenovirus vector
- 20 encoding tyrosine hydroxylase activity may enter human CNS cells in primary dissociated cultures. *Int. J. Dev. Neurosci.* **14**, 613-619.
- LIN, Q., CUNNINGHAM, L.A., EPSTEIN, L.G., PECHAN, P.A., SHORT, M.P., FLEET C., and BOHN, M.C. (1997). Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor. *Hum. Gene*
- 25 Ther. **8**, 331-339.
- LUNDBERG, C., HORELLOU, P., MALLET, J., and BJÖRKLUND, A. (1996). Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: *in vitro* characterization and *in vivo* effects in the rat Parkinson model. *Exp. Neurol.* **139**, 39-53.
- 30 MARON, A., HAVAUX, N., LE ROUX, A., KNOOPS, B., PERRICAUDET, M., and OCTAVE, J.N. (1997). Differential toxicity of ganciclovir for rat neurons and

astrocytes in primary culture following adenovirus-mediated transfer of the HSVtk gene. *Gene Ther.* **4**, 25-31.

MARTINEZ-SERRANO, A., and BJORKLUND, A. (1997). Immortalized neural progenitor cells for CNS gene transfer and repair. *Trends Neurosci.* **20**, 530-538.

- 5   McCARTHY, M., WOOD, C., FEDOSEYEVA, L., and WHITTEMORE, S.C. (1995). Media components influence viral gene expression assays in human fetal astrocyte cultures. *J. Neurovirol.* **1**, 275-285.

MILLER, N., and WHELAN, J. (1997) Progress in transcriptionally targeted and regulatable vectors for genetic therapy. *Hum. Gene Ther.* **8**, 803-815.

- 10   OLANOW, C.W., KORDOWER, J.H., and FREEMAN, T.B. (1996). Fetal nigral transplantation as a therapy for Parkinson's disease. *Trends Neurosci.* **19**, 102-109.

PERZELOVA, A. and MARES, V. (1993). Appearance of GFAP-positive cells in adult human brain cultures spontaneously decelerated in growth. *Glia* **7**, 237-244.

- 15   PUNDT, L.L., KONDOH, T., and LOW, W.C. (1995). The fate of human glial cells following transplantation in normal rodents and rodent models of neurodegenerative disease. *Brain Res.* **695**, 25-36.

REINHARD Jr, J.F., SMITH, G.K., and NICHOL, C.A. (1986). A rapid and sensitive assay for tyrosine-3-monooxygenase based upon the release of  $^3\text{H}_2\text{O}$  and adsorption of [ $^3\text{H}$ ]-tyrosine by charcoal. *Life Sci.* **39**, 2185-2189.

- 20   RIDET, J.L., MALHOTRA, S.K., PRIVAT, A., and GAGE, F.H. (1997). Reactive astrocytes: cellular and molecular cues to biological function. *Trends Neurosci.* **20**, 570-577.

- RIDOUX, V., ROBERT, J.J., ZHANG, X., PERRICAUDET, M., MALLET, J., and LEGAL LA SALLE, G. (1994). The use of adenovirus vectors for intracerebral grafting  
25   of transfected nervous cells. *NeuroReport* **5**, 801-804.

SABATE, O., HORELLOU, P., VIGNE, E., COLIN, P., PERRICAUDET, M., BUCARON, M.H., and MALLET, J. (1995). Transplantation to the rat brain of human neural progenitors that were genetically modified using adenovirus. *Nature Genet.* **9**, 256-260.

- 30   SAEZ, E., NO, D., WEST, A., and EVANS, R.M. (1997) Inducible gene expression in mammalian cells and transgenic mice. *Curr. Opin. Biotechnol.* **8**, 608-616.

- SHOCKETT, P., DIFILIPPANTONIO, M., HELLMAN, N., and SCHATZ, D.G. (1995). A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. *Proc. Natl. Acad. Sci. USA* **92**, 6522-6526.
- 5 STACHOWIAK, M.K., MOFFETT, J., MAHER, P., TUCHOLSKI J., and STACHOWIAK, E.K. (1997). Growth factor regulation of cell growth and proliferation in the nervous system. *Mol. Neurobiol.* **15**, 257-283.
- STREIT, W.J. (1990). An improved staining method for rat microglial cells using the lectin from *Griffonia simplicifolia* (GSA I-B4). *J. Histochem. Cytochem.* **38**, 1683-10 1686.
- TAYLOR, R. (1997). Cell vehicles for gene transfer to the brain. *Neuromuscul. Dis.* **7**, 343-351.
- WOLFF J.F., FISHER, L.J., XU, L., JINNAH, H.A., LANGLAIS, P.J., IUVONE, P.M., O'MALLEY, K.L., ROSENBERG, M.B., SHIMOHAMA, S., FRIEDMANN, T., and 15 GAGE, F.H. (1989). Grafting fibroblasts genetically modified to produce L-Dopa in a rat model of Parkinson's disease. *Proc. Natl. Acad. Sci. USA* **86**, 9011-9014.
- YONG, V.W., MOUMDJIAN, R., YONG, F.P., RUIJS, T.C.G., FREEDMAN, M.S., CASHMAN, N., and ANTEL, J.P. (1991). Gamma-interferon promotes proliferation of adult human astrocytes in vitro and reactive gliosis in the adult mouse brain in 20 vivo. *Proc. Natl. Acad. Sci. USA* **88**, 7016-7020.
- YONG, V.W., TEJADA-BERGES, T., GOODYER, C.G., ANTEL, J.P., and YONG, F.P. (1992). Differential proliferative response of human and mouse astrocytes to gamma-interferon. *Glia* **6**, 269-280
- YOSHIMOTO, Y., LIN, Q., COLLIER, T., FRIM, D., BREAKFIELD, X.O., and 25 BOHN, M.C. (1995). Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. *Brain Res.* **691**, 25-36.

CLAIMS

1. A method of producing an essentially pure population of astrocytes, the method comprising
- 5 a) introducing a preparation of astrocytes to a culture vessel,  
b) incubating the astrocytes from step a) under conditions enabling attachment of the astrocytes to the culture vessel, and  
c) removing cells which have not attached to the culture vessel at a time of about 48 hours from the beginning of step a).
- 10 2. The method according to claim 1, wherein the astrocytes are human astrocytes.
3. The method according to claim 2, wherein the human astrocytes are human adult astrocytes.
- 15 4. The method according to claim 1, wherein said essentially pure population of astrocytes is essentially free of microglial cells.
5. The method according to claim 1, wherein the astrocytes are primary astrocytes
- 20 obtained by surgical resection from a patient.
6. The method according to claim 1, wherein unattached cells are removed from the culture vessel by a change of culture media.
- 25 7. The method according to claim 1, further comprising a step d) of introducing a nucleic acid into the astrocytes.
8. The method according to claim 7, wherein the nucleic acid is introduced into the astrocytes with a viral vector.
- 30 9. The method according to claim 8, wherein the viral vector is selected from the group consisting of adenovirus, Herpes virus, AAV, retrovirus and vaccinia virus.

10. The method according to claim 9, wherein the viral vector is a replication defective adenoviral vector.
- 5 11. The method according to claim 7, wherein the nucleic acid is introduced into the astrocytes by calcium-phosphate precipitation, liposome-mediated transfection, cationic lipid transfection, or lipopolyamine-mediated transfection.
12. The method according to claim 7, wherein the nucleic acid encodes a neuroactive  
10 substance.
13. An essentially pure population of astrocytes produced by the method according to claim 1.
- 15 14. An essentially pure population of astrocytes.
15. The population of astrocytes according to claim 14, wherein the astrocytes are human astrocytes.
- 20 16. The population of astrocytes according to claim 15, wherein the human astrocytes are human adult astrocytes.
17. The population of astrocytes according to claim 16, wherein said population of astrocytes is essentially free of microglial cells.
- 25 18. The population of astrocytes according to claim 14, wherein the astrocytes are primary astrocytes obtained by surgical resection from a patient.
19. The population of astrocytes according to claim 14, further comprising an  
30 exogenous nucleic acid.

20. The population of astrocytes according to claim 19, wherein the nucleic acid is introduced into the astrocytes with a viral vector.

21. The population of astrocytes according to claim 20, wherein the viral vector is  
5 selected from the group consisting of adenovirus, Herpes virus, AAV, retrovirus and vaccinia virus.

22. The population of astrocytes according to claim 21, wherein the viral vector is a replication defective adenoviral vector.

10

23. The population of astrocytes according to claim 19, wherein the nucleic acid is introduced into the astrocytes by calcium-phosphate precipitation, liposome-mediated transfection, cationic lipid transfection, or lipopolyamine-mediated transfection.

15 24. The population of astrocytes according to claim 19, wherein the nucleic acid encodes a neuroactive substance.

25. The population of astrocytes according to claim 19, wherein said nucleic acid is DNA or RNA.

20

26. The population of astrocytes according to claim 25, wherein said nucleic acid is a DNA encoding a protein, polypeptide or peptide.

27. The population of astrocytes according to claim 26, wherein said protein,  
25 polypeptide or peptide is selected from the group consisting of growth factors, neurotrophic factors, and enzymes.

28. The population of astrocytes according to claim 25, wherein said nucleic acid is a DNA encoding an antisense-RNA or a ribozyme.

30

29. The population of astrocytes according to claim 24, wherein said nucleic acid is operably linked to a regulatory region.

30. The population of astrocytes according to claim 29, wherein the regulatory region comprises a regulatable promoter, an inducible promoter, a neural cell-specific promoter or a viral promoter.

5

31. An implant comprising a population of astrocytes according to claim 14.

32. A composition comprising an essentially pure population of astrocytes comprising an exogenous nucleic acid encoding a neuroactive substance.

10

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190



Figure 1A



Figure 1B

2/5



Figure 2A



Figure 2B




Figure 3A





Figure 3B



**Figure 4A**



Figure 4B



Figure 4C

5/5





Figure 5



UNITED STATES OF AMERICA

**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).  
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**Human Adult Astrocytes, Their Preparation and Uses Thereof**

and the specification of which ☐ is attached hereto (Attorney Docket No. \_\_\_\_\_)  
(check one) ☒ was filed on **13 June 2001** as U.S. Application Number **09/868,026**  
and was amended on \_\_\_\_\_ (if applicable).  
☐ was described and claimed in PCT Int'l Application Number \_\_\_\_\_ filed on \_\_\_\_\_  
and as amended under PCT Article 19 on \_\_\_\_\_ (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above.

I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.

☐ I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority: Number \_\_\_\_\_ Country \_\_\_\_\_ Day/Month/Year Filed \_\_\_\_\_

Prior Foreign Appln(s): Number \_\_\_\_\_ Country \_\_\_\_\_ Day/Month/Year Filed \_\_\_\_\_

☒ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:

**60/114,758** **05 January 1999**  
Number Filing Date

☒ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

**PCT/IB00/00615** **05 January 2000** **Pending**  
Application Serial No. Filing Date Status (Patented, Pending)

I/We hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as my/our attorneys and/or agents with full power to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

**Customer No.: 005487**

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☐ Additional names and signatures are attached.

1. Full name: **Jean-Luc Ridet**

Signature: Jean-Luc Ridet

Date: October 18, 01

Country of Citizenship: France

Residence: Lausanne, Switzerland CHX  
(City and State/City and Country only)

P. O. Address: Route d'Oron 77/514, CH-1010  
Lausanne, Switzerland

2. Full name: **Jacques Mallet**

Signature: Jacques Mallet

Date: October 18, 01

Country of Citizenship: France

Residence: Paris, France FLX  
(City and State/City and Country only)

P. O. Address: 18, rue Charcot, F-75013  
Paris, France

3. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_  
(City and State/City and Country only)

P. O. Address: \_\_\_\_\_  
\_\_\_\_\_

4. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_  
(City and State/City and Country only)

P. O. Address: \_\_\_\_\_  
\_\_\_\_\_

5. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_  
(City and State/City and Country only)

P. O. Address: \_\_\_\_\_  
\_\_\_\_\_

6. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_  
(City and State/City and Country only)

P. O. Address: \_\_\_\_\_  
\_\_\_\_\_

7. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_  
(City and State/City and Country only)

P. O. Address: \_\_\_\_\_  
\_\_\_\_\_

8. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_


Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_  
(City and State/City and Country only)

P. O. Address: \_\_\_\_\_  
\_\_\_\_\_

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206  
P.O. Box 6800  
Mail Code EMC-G1  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-  
Telefax (908) 231-2626

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not  
present  
for scanning. (Document title)

☒ *Scanned copy is best available. drawing is dark*